Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $793000.0.

  • Apellis Pharmaceuticals' Cash from Financing Activities fell 6880.41% to $793000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 9757.25%. This contributed to the annual value of $149.2 million for FY2024, which is 6216.95% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Cash from Financing Activities of $793000.0 as of Q3 2025, which was down 6880.41% from $6.6 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Cash from Financing Activities peaked at $391.1 million during Q1 2023, and registered a low of -$15.9 million during Q4 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' median Cash from Financing Activities value was $2.5 million (recorded in 2024), while the average stood at $68.9 million.
  • Data for Apellis Pharmaceuticals' Cash from Financing Activities shows a peak YoY increase of 2298235.29% (in 2022) and a maximum YoY decrease of 20461.78% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Cash from Financing Activities stood at $384.0 million in 2021, then crashed by 104.15% to -$15.9 million in 2022, then soared by 75.46% to -$3.9 million in 2023, then decreased by 2.22% to -$4.0 million in 2024, then skyrocketed by 119.82% to $793000.0 in 2025.
  • Its last three reported values are $793000.0 in Q3 2025, $6.6 million for Q2 2025, and $274000.0 during Q1 2025.